Vesalius Biocapital led a €15m Series C round in HepaRegeniX.

Vesalius Biocapital, a European life sciences venture capital investor, led a €15m Series C round in HepaRegeniX, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, with participation from Novo, Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds. “We are thrilled to secure this significant financing, which underscores the confidence our investors have in our science and our capabilities to bring effective treatments to patients suffering from liver diseases. With the new funds, HepaRegeniX will advance with its clinical plans for a Phase Ib study in the US and an international Phase IIa study to enhance liver recovery and prevent liver failure,” Elias Papatheodorou, HepaRegeniX Chairperson.